Related Experiment Videos
Mutagenic and recombinogenic effects of the antitumor antibiotic anthramycin
Abstract:
Anthramycin, one of the pyrrolo(1,4)benzodiazepine antibiotics with potent antitumor activity, was tested for its effects on a number of genetic parameters. The results show that this antibiotic is nonmutagenic in the Ames strains of Salmonella typhimurium while mutagenic in only one and antimutagenic in the rest of the genes tested in the eukaryotic organism Saccharomyces cerevisiae. The antibiotic is, however, a potent recombinogen inasmuch as it induced mitotic crossing over, mitotic gene conversion, and possibly other chromosomal alterations in a diploid strain of S. cerevisiae. These studies emphasize the need for a battery of test systems including eukaryotic organisms to detect the genetic activity of certain antitumor drugs. The importance of considering data distinguishing between highly mutagenic and poorly mutagenic cancer chemotherapeutic agents is also discussed.
Insights
Anthramycin, an antitumor drug, is not mutagenic in bacteria but is mutagenic and highly recombinogenic in yeast. These findings highlight the need for eukaryotic testing of anticancer agents.
Area of Science:
- Pharmacology
- Genetics
- Toxicology
Background:
- Anthramycin is a pyrrolo(1,4)benzodiazepine antibiotic with known antitumor activity.
- Understanding the genotoxicity of antitumor drugs is crucial for patient safety and drug development.
Purpose of the Study:
- To evaluate the mutagenic and recombinogenic potential of Anthramycin.
- To assess the utility of eukaryotic test systems for genotoxicity testing of anticancer drugs.
Main Methods:
- Bacterial mutagenicity testing using Ames strains of Salmonella typhimurium.
- Eukaryotic genetic toxicity assays in Saccharomyces cerevisiae, including mutagenicity, antimutagenicity, and recombination assays (mitotic crossing over, gene conversion).
Main Results:
- Anthramycin was nonmutagenic in Salmonella typhimurium.
- In Saccharomyces cerevisiae, Anthramycin exhibited mutagenic activity in one gene and antimutagenic activity in others.
- Anthramycin was a potent inducer of mitotic recombination and gene conversion in yeast, suggesting chromosomal alterations.
Conclusions:
- Eukaryotic test systems, such as Saccharomyces cerevisiae, are essential for comprehensive genotoxicity assessment of antitumor drugs.
- Distinguishing between highly and poorly mutagenic anticancer agents is important for therapeutic decision-making.